Compare PUBM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PUBM | PRAX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.5M | 4.0B |
| IPO Year | 2020 | 2020 |
| Metric | PUBM | PRAX |
|---|---|---|
| Price | $9.18 | $267.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | $18.45 | ★ $304.43 |
| AVG Volume (30 Days) | 650.3K | ★ 1.1M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $288,382,000.00 | $7,463,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $7.01 | $26.70 |
| 52 Week High | $17.32 | $278.44 |
| Indicator | PUBM | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 71.53 |
| Support Level | $8.91 | $251.00 |
| Resistance Level | $9.24 | $278.44 |
| Average True Range (ATR) | 0.34 | 17.08 |
| MACD | 0.00 | 6.49 |
| Stochastic Oscillator | 65.48 | 90.84 |
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.